NYSE - Delayed Quote • USD
Merck & Co., Inc. (MRK)
At close: April 18 at 4:00 PM EDT
Pre-Market: 4:24 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 24 | 23 |
| Avg. Estimate | 1.94 | 2.11 | 8.56 | 9.8 |
| Low Estimate | 1.76 | 1.84 | 8.44 | 9.12 |
| High Estimate | 2.25 | 2.27 | 8.78 | 10.46 |
| Year Ago EPS | 1.4 | -2.06 | 1.51 | 8.56 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 24 | 23 |
| Avg. Estimate | 15.16B | 15.87B | 63.79B | 67.99B |
| Low Estimate | 14.87B | 15.34B | 62.72B | 66.08B |
| High Estimate | 15.68B | 16.18B | 64.98B | 70.14B |
| Year Ago Sales | 13.78B | 15.04B | 60.12B | 63.79B |
| Sales Growth (year/est) | 10.00% | 5.50% | 6.10% | 6.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.32 | -2.18 | 1.78 | -0.11 |
| EPS Actual | 1.4 | -2.06 | 1.94 | 0.03 |
| Difference | 0.08 | 0.12 | 0.16 | 0.14 |
| Surprise % | 6.10% | 5.50% | 9.00% | 127.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.94 | 2.11 | 8.56 | 9.8 |
| 7 Days Ago | 1.99 | 2.07 | 8.57 | 9.76 |
| 30 Days Ago | 2.06 | 2.02 | 8.58 | 9.77 |
| 60 Days Ago | 1.91 | 1.87 | 7.95 | 9.06 |
| 90 Days Ago | 2 | 2.08 | 8.51 | 9.55 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 3 | 3 |
| Up Last 30 Days | 4 | 9 | 8 | 9 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | MRK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 38.60% | -- | -- | 0.80% |
| Next Qtr. | 202.40% | -- | -- | 9.60% |
| Current Year | 466.90% | -- | -- | 4.50% |
| Next Year | 14.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 67.56% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -11.64% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Maintains | Berenberg: Buy to Buy | 4/8/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
| Reiterates | Truist Securities: Buy to Buy | 3/28/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/27/2024 |
Related Tickers
BMY Bristol-Myers Squibb Company
48.30
+0.96%
ABBV AbbVie Inc.
164.66
+0.25%
AMGN Amgen Inc.
262.75
-0.50%
JNJ Johnson & Johnson
145.74
+0.67%
PFE Pfizer Inc.
25.39
-0.12%
LLY Eli Lilly and Company
745.95
-0.64%
GILD Gilead Sciences, Inc.
66.16
-1.15%
OGN Organon & Co.
17.86
-0.06%
AZN AstraZeneca PLC
68.36
-0.25%
GSK GSK plc
39.27
-0.83%